1. Market Research
  2. > Biotechnology
  3. > Biopharmaceutical Market Trends
  4. > Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

The leading pharmaceutical players continue to face the combined threats of a difficult operating environment and patent losses while struggling to deliver on pipeline potential. Externalization strategies are a key means to boost future revenues and, indeed more imminently, to satisfy shareholder demands. However, the increasing size of the leading biopharmaceutical companies is necessitating their involvement in growing the numbers and size of deals year by year. This in itself, along with the rising financial firepower of the mid-tier players, has increased the level of competition for the most attractive targets.

Increased competition in the marketplace for M&A and licensing deals can artificially inflate the cost of these deals, distorting the balance of value, risk and return. As a result companies must employ more rigorous selection processes and expand search criteria to consider more diverse options if they are to maximize their returns on investment.

The report, “Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy”, was written to support team and corporate strategic initiatives around the options that exist to grow revenues through externalization, whether by M&A or licensing. CBR Pharma Insights provides in-depth analysis on the deals being done today, the trends being seen over time, and the strategies employed throughout the industry.

Scope

- Trends in recent deal activity
- Successful deal making
- Future deal activity

Key Reasons to Purchase

- Understand and evaluate the strategies being used by companies of all sizes to support future revenue growth
- Benefit from CBR’s case study analysis of the different types of deals being done in the current & future biopharma industry
- Access data and trends analysis of the types of deals taking place and which therapeutic areas are showing the most activity
- Gain insights around the steps that need to be taken in order to best secure a successful deal
- Learn who the key companies are to watch for in the coming year, the motivations behind the deals they are doing, and identify which ones relate to your business strategies

Table Of Contents

Biopharma MandA and Deal Making - Understanding the Latest Trends to Optimize Future Strategy
Executive Summary

Chapter 1: Introduction
What is driving the increased use of externalization in biopharma industry strategies
Externalization strategies: the options
Benefits of different deal types from MandA to arms length licensing

Chapter 2: Trends in recent deal activity
MandA deal trends
Key acquisitions in 2012 and the motives behind them
Most acquisitive companies
Licensing deal trends (Type of deal, Therapy area, Phase)
Divesting - the other extreme
Focus on: Deal activity in the generics sector

Chapter 3: Successful deal making
Key steps to successful deal making
Shift to earlier stage deals
Differentiating capabilities to position company as "partner of choice“
Focus on: Joint ventures in emerging markets

Chapter 4: Future deal activity
Key companies to watch in 2013

Appendix

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

R&D Drug Pipeline Database: 1-Year Subscription

R&D Drug Pipeline Database: 1-Year Subscription

  • $ 6600
  • Industry report
  • November 2016
  • by La Merie Publishing

R&D Drug Pipeline Database: 1-Year Subscription Subscription to La Merie Publishing’s proprietary R&D Drug Pieline Database provides 24/7 online access to information about more than 21,000 project entries ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6650
  • Industry report
  • November 2016
  • by BCC Research

This cancer vaccines report by BCC Research explores present and future strategies within the market which includes prophylactic vaccines and therapeutic vaccines. Use this report to: - Analyze the global ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.